Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.8849 USD -1.08% Market Closed
Market Cap: 163.2m USD

Nektar Therapeutics
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nektar Therapeutics
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Operating Expenses
-$199m
CAGR 3-Years
27%
CAGR 5-Years
18%
CAGR 10-Years
0%
Johnson & Johnson
NYSE:JNJ
Operating Expenses
-$38B
CAGR 3-Years
-3%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Expenses
-$24.9B
CAGR 3-Years
2%
CAGR 5-Years
-24%
CAGR 10-Years
-11%
Pfizer Inc
NYSE:PFE
Operating Expenses
-$29.4B
CAGR 3-Years
-11%
CAGR 5-Years
1%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Operating Expenses
-$26.7B
CAGR 3-Years
-11%
CAGR 5-Years
-7%
CAGR 10-Years
-4%
Eli Lilly and Co
NYSE:LLY
Operating Expenses
-$18.6B
CAGR 3-Years
-12%
CAGR 5-Years
-10%
CAGR 10-Years
-5%

Nektar Therapeutics
Glance View

Market Cap
163.2m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
0.6969 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is Nektar Therapeutics's Operating Expenses?
Operating Expenses
-199m USD

Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Operating Expenses amounts to -199m USD.

What is Nektar Therapeutics's Operating Expenses growth rate?
Operating Expenses CAGR 10Y
0%

Over the last year, the Operating Expenses growth was 1%. The average annual Operating Expenses growth rates for Nektar Therapeutics have been 27% over the past three years , 18% over the past five years .

Back to Top